Ingersoll Rand (IR) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 is a moderate bar with a slight beat bias — consensus expects organic revenue to inflect to slightly positive for the first time in several quarters, and management guided explicitly for sequential margin improvement from Q1; the biggest swing factor is whether ITS margins are tracking toward the guided 50–100 bps year-over-year decline or surprising to the upside as tariff comps begin to ease.

Heading into Q2 2026, Ingersoll Rand faces a consensus bar that is achievable but not easy: the street is modeling ~$1.96B in revenue (+4% YoY) and adjusted EPS of ~$0.82, both of which imply a modest step-up from Q1's $1.85B / $0.77 print. Management guided explicitly for organic revenue to be "flattish to slightly up" in Q2 — a meaningful improvement from Q1's -0.3% organic decline — and for sequential margin improvement, though ITS margins are still expected to be down 50–100 bps year-over-year as tariff pricing remains dilutive and volume recovery is gradual. Estimate revisions have drifted modestly lower since the Q1 print (Q2 EPS consensus slipped from ~$0.82 to ~$0.82, essentially flat), suggesting the street has largely digested the tariff headwind narrative and is not pricing in a meaningful upside surprise. The stock has recovered from its post-Q1 lows (~$68) to ~$84–86, essentially recouping the earnings-day selloff and then some, which means the multiple has re-expanded and the stock is no longer pricing in a miss — a clean beat-and-raise would likely be needed to drive further upside. The key wildcard is the pace of Middle East long-cycle order recovery (management said ~1/3 recovered in April) and whether PST's life sciences momentum — which delivered double-digit order growth in Q1 driven by biopharma reshoring — has continued into Q2, as that segment is the primary margin expansion engine for the year.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a moderate bar — organic revenue inflection to slightly positive is the key test, while ITS segment EBITDA margin is the bigger swing factor given five consecutive quarters of year-over-year compression and management's explicit Q2 guidance of -50 to -100 bps YoY.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of July 29, 2026.

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Adj. EPS & Adj. EBITDA Margin)

Pattern: IR has a consistent track record of beating on EPS (5 of last 8 quarters) but has repeatedly missed or come in light on EBITDA margin (4 of last 8 quarters), reflecting the persistent gap between volume-driven margin leverage and tariff/pricing headwinds — the margin line remains the key source of earnings-day volatility.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Full-year 2026 guidance was reaffirmed in full at Q1 earnings (April 28, 2026) with no changes; no post-earnings guidance revisions have been issued. Tone is cautiously constructive — management is confident in H2 margin recovery but has not raised the bar.

Source: IR Q1 2026 Earnings Release (April 28, 2026) and Q1 2026 Earnings Call Transcript (April 29, 2026); Visible Alpha Consensus and Actuals Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have drifted modestly lower since the Q1 print — Q2 EPS consensus slipped ~$0.08 from the January 2026 peak of ~$0.70 to ~$0.82 (note: the January figure reflected a different period mix; on an apples-to-apples basis, Q2 EPS has been essentially stable since the Q1 print). FY 2026 EPS consensus of ~$3.50 sits precisely at the guidance midpoint, suggesting the street is not pricing in a raise — any upside to ITS margins or organic volume in Q2 could catalyze upward revisions.

Estimates have been remarkably stable since the Q1 print — essentially no revision in either direction across all key KPIs. This stability reflects the market’s acceptance of management’s guidance framework, but also means there is no estimate cushion built in: consensus is sitting precisely at the guidance midpoint, so any upside to organic volume or ITS margins would require upward revisions and could be a meaningful catalyst.

Source: Visible Alpha Consensus and Actuals Data.

5. Stock Performance

Key Takeaway: IR’s post-Q1 selloff (-5% on earnings day) was driven by sentiment and multiple compression rather than estimate cuts — the stock has since fully recovered and is now up ~4% vs. the Q1 earnings close, outperforming XLI (+3%) but lagging the S&P 500 (+3%) on an indexed basis; the recovery was multiple-driven as estimates barely moved, suggesting the stock is pricing in execution on H2 guidance.

IR closed at $81.19 on April 28, 2026 (Q1 earnings day). The stock sold off to a low of ~$68.54 by May 19 before recovering sharply. As of July 28, 2026, IR closed at $86.50, representing a +6.5% gain from the Q1 earnings close. Over the same period, XLI gained approximately +6.7% (from $170.98 to $182.49) and the S&P 500 gained approximately +4.1% (from $711.69 to $740.86). IR broadly tracked the industrial sector (XLI) after recovering from its post-earnings dip, with a notable spike on July 16 (to $84.78) likely reflecting sector rotation and improving industrial PMI data. The stock’s recovery without meaningful upward estimate revisions confirms the move was sentiment/multiple-driven rather than earnings-driven, implying the stock needs a genuine beat-and-raise to sustain further upside from current levels.

Benchmark: XLI (Industrial Select Sector SPDR ETF) — appropriate for IR’s multi-industry / specialty industrial machinery classification.

Source: Stock Price Data (Yahoo Finance).

Note: Indexed to 100 at April 28, 2026 (Q1 2026 earnings date). Key event: July 16, 2026 — IR spiked +7.2% in a single session, likely driven by sector rotation into industrials and improving macro data (U.S. PMI turning positive). Source: Stock Price Data (Yahoo Finance).

6. Material News & Developments

Key Takeaway: The most important post-Q1 development is the continued execution of the M&A pipeline — Fox S.r.l. closed May 4, 2026, adding to PST’s hydropneumatic accumulator capabilities — while the shareholder approval of a new omnibus incentive plan signals management alignment with long-term value creation.

• May 4, 2026 — Fox S.r.l. Acquisition Closed (PST Segment): IR closed the acquisition of Fox S.r.l., an Italian manufacturer of hydropneumatic accumulators and pulsation dampeners. The deal enhances PST’s dosing pump capabilities and adds to the life sciences / precision fluid handling platform. This is one of four bolt-on deals closed year-to-date as of June 2026, contributing to the targeted ~+2% M&A revenue growth for FY 2026. Implication: Incremental PST revenue contribution in Q2; supports the M&A revenue growth target.
• June 16, 2026 — Shareholders Approve New Omnibus Incentive Plan (8-K): IR shareholders approved a new omnibus incentive plan at the annual meeting. Implication: Signals management and board alignment with long-term performance targets (ITS 30% EBITDA margin by 2027, PST mid-30s); no near-term financial impact.
• July 1, 2026 — Q2 2026 Earnings Call Scheduled: IR formally announced the Q2 2026 earnings release and conference call for July 31, 2026 at 8:00 AM ET. No pre-announcement or guidance update was included in the press release. Implication: Absence of a pre-announcement is a mild positive signal — management did not feel compelled to warn on results.
• Ongoing — Biopharma Reshoring Tailwind (Life Sciences / PST): Multiple peer companies (DOV, XYL) have confirmed accelerating demand in biopharma and life sciences end markets, consistent with IR’s Q1 commentary about double-digit life sciences order growth driven by API production reshoring in the U.S. Implication: Positive read-through for PST’s life sciences sub-segment in Q2.
• Ongoing — U.S. PMI Turned Positive: The U.S. ISM Manufacturing PMI moved above 50 for the first time in several quarters, consistent with IR management’s Q1 commentary about short-cycle stabilization. Graco (GGG) confirmed “PMI starting to turn positive” and broad-based industrial growth in its Q2 2026 earnings call. Implication: Supports IR’s short-cycle compressor and tool demand recovery narrative heading into Q2.
• Ongoing — M&A Pipeline Active (10 LOIs as of Q1): IR disclosed 10 transactions at LOI stage as of Q1 earnings, with a potential deal exceeding $1B in purchase price in the funnel (not yet at LOI). Four deals closed year-to-date as of June 2026. Implication: M&A optionality remains a key differentiator; any announcement of a larger deal could be a significant catalyst.
• Ongoing — Middle East Long-Cycle Order Recovery: Management stated ~1/3 of the ~$40M in delayed Middle East orders had already been recovered in April 2026. Full recovery expected throughout the balance of 2026. Implication: Q2 ITS organic orders should benefit from partial recovery; watch for commentary on the remaining ~$27M.

7. Insider Transaction Activity

Key Takeaway: No open-market insider purchases or discretionary sales were identified in the SEC Form 4 filings for IR in the 60-day window prior to July 29, 2026. The only Form 4 activity identified was a single filing in May 2026, which appears to be a routine equity award or plan-related transaction rather than a discretionary open-market trade. Nothing stands out as a meaningful insider signal heading into Q2 earnings.

8. Peer Commentaries & Read-Through

Key Takeaway: Peers reporting Q2 2026 results in the last 60 days (DOV, GGG, ITW, XYL) collectively paint a constructive picture for IR’s Q2 print and H2 outlook: broad-based industrial demand is recovering, book-to-bill ratios are above one, PMI is turning positive, and biopharma/life sciences demand is accelerating — all directly supportive of IR’s ITS short-cycle recovery and PST life sciences growth narratives. The primary risk flagged by peers is margin timing (price-cost lags, tariff comps) rather than demand, which aligns with IR’s own H2-weighted margin recovery guide.

Note: All commentary below is forward-looking, drawn exclusively from Q2 2026 earnings calls (reported July 23–28, 2026) and pertains to the Q3 2026 / H2 2026 outlook. Retrospective Q2 2026 results commentary has been excluded.

Dover Corporation (DOV) — Q2 2026 Earnings Call, July 23, 2026

Relevance to IR: DOV is a direct peer in industrial flow control, pumps, and precision components. Its commentary on order momentum, book-to-bill, biopharma, and tariff dynamics is a high-quality read-through for both IR’s ITS and PST segments.

• Order Momentum & Book-to-Bill (H2 2026 Outlook): DOV reported consolidated bookings up 15% on a trailing 12-month basis with book-to-bill “well above one,” providing “further visibility and confidence in our outlook.” Management stated: “The breadth of our order growth is important and points to continued top-line strength in the second half.”
• Read-Through for IR: Directly supportive of IR’s ITS short-cycle recovery narrative and management’s guide for low single-digit organic growth in H2 2026. A book-to-bill well above one at DOV suggests the industrial demand environment is genuinely improving, not just a timing artifact.
• Full-Year Guidance Raised: DOV raised its full-year adjusted EPS guidance, committing to “double-digit adjusted EPS growth consistent with Dover’s long-term performance trajectory.” Management expects “positive organic growth across all five segments” in H2 2026.
• Read-Through for IR: A guidance raise from a direct peer in the same industrial end markets is a positive signal for IR’s ability to reaffirm or potentially raise its own FY 2026 guidance on July 31.
• Biopharma (PST Read-Through): DOV’s biopharma business is “performing well, driven by new product introductions and the consumable nature of its revenue stream.” This is consistent with IR’s Q1 commentary about double-digit life sciences order growth driven by biopharma reshoring.
• Read-Through for IR: Positive read-through for IR’s PST life sciences sub-segment — biopharma demand appears to have continued into Q2 and beyond.
• Cash Flow Acceleration in H2: DOV expects “cash flow generation to accelerate meaningfully in the second half, driven by seasonal working capital liquidation in Q3 and Q4.”
• Read-Through for IR: Consistent with IR’s own H2-weighted free cash flow profile and ~95% FCF conversion target.
• M&A Markets Improving: DOV noted “industrial M&A markets have improved this year, and our acquisition pipeline has a number of interesting opportunities in attractive end markets.”
• Read-Through for IR: Supportive of IR’s active M&A pipeline (10 LOIs); improving deal availability could accelerate IR’s bolt-on cadence.

Graco Inc. (GGG) — Q2 2026 Earnings Call, July 23, 2026

Relevance to IR: GGG is a direct peer in fluid handling, pumps, and dispensing equipment. Its commentary on short-cycle industrial demand, PMI, contractor/industrial end markets, and pricing is a strong read-through for IR’s ITS compressor and tool businesses.

• Short-Cycle Demand Recovery & Backlog (H2 2026 Outlook): GGG reported its most recent six-week booking average up 14% versus last year, with backlog up $57M (+28%) from the beginning of the year as of July 17. Management stated: “That gives us a lot of momentum heading into the back half.”
• Read-Through for IR: Strongly supportive of IR’s short-cycle ITS recovery narrative. A 14% booking acceleration at GGG — a company with similar short-cycle industrial exposure — suggests the demand environment has genuinely improved since Q1.
• PMI Turning Positive (Industrial Segment): GGG management characterized industrial growth as “pretty broad based” and noted “the PMI start to turn positive,” with investments in machinery manufacturing and general industrial applications and “pretty healthy MRO channels.”
• Read-Through for IR: Directly corroborates IR management’s Q1 commentary about U.S. ISM moving above 50 and short-cycle stabilization. A positive PMI read from GGG in Q2 supports IR’s organic revenue inflection to slightly positive in Q2.
• Contractor Segment Recovery (H2 2026): GGG expressed cautious optimism that “we’ve kind of seen the worst of the macro market conditions that business has had to face over the last 4 or 5 years” and expects to “grow off the current base.”
• Read-Through for IR: Mild positive for IR’s ITS compressor and tool businesses, which have similarly faced multi-quarter organic volume headwinds.
• Pricing Discipline Maintained: GGG confirmed its “price-cost equation is positive” and plans to “stick to historic price cadence” (price increases at the beginning of the year). No need for reactive pricing actions.
• Read-Through for IR: Positive for IR’s price-cost narrative — if GGG’s price-cost is positive, it suggests the industrial pricing environment is rational and IR’s own price-cost turning “more positive in H2” is credible.
• Data Center / Infrastructure Demand: GGG highlighted “good demand in protective coatings and foam” benefiting from “commercial construction, infrastructure and industrial project activity, including investments tied to data centers, energy and manufacturing.” Semiconductor demand expected to “continue its strong year” with momentum lasting “through the end of this year and into next year.”
• Read-Through for IR: Positive for IR’s ITS long-cycle project funnel and PST’s precision technology businesses that serve semiconductor and industrial automation end markets.

Illinois Tool Works (ITW) — Q2 2026 Earnings Call, July 28, 2026

Relevance to IR: ITW is a large-cap multi-industry peer with broad industrial end-market exposure. Its guidance raise, margin commentary, and demand signals are a high-quality read-through for IR’s H2 margin recovery thesis.

• Full-Year Guidance Raised — Organic Growth & EPS (H2 2026 Outlook): ITW raised full-year organic growth guidance by 1.5 percentage points to a new midpoint of 3.5% (range: 3%–4%), implying “sustained organic growth of 4.5% in the second half.” GAAP EPS guidance raised by $0.15 to a midpoint of $11.45 (+9% YoY). Management stated: “We’re very confident going into the back half of the year based on what we see in terms of the order rates.”
• Read-Through for IR: A guidance raise from the largest multi-industry peer is a strong positive signal for the industrial demand environment. If ITW can sustain 4.5% organic growth in H2, IR’s guide for low single-digit organic growth in H2 looks achievable and potentially conservative.
• All Seven Segments to Deliver Positive Organic Growth & Margin Expansion: ITW expects “all seven segments to deliver both positive organic growth and expand operating margins” in H2 2026. Enterprise initiatives expected to contribute “more than 100 basis points” to margins.
• Read-Through for IR: Directly supportive of IR’s H2 margin recovery thesis — if ITW can expand margins across all segments in H2, IR’s ITS margin recovery (guided to be back-end weighted) is credible.
• Price-Cost Lag Persisting into Q3, Improving in Q4: ITW noted a “timing lag between inflation and price adjustments” that diluted margins by 40 bps in Q2, expected to persist “a little bit into Q3” with “further improvement in Q4.” Full-year average headwind estimated at ~20 bps. Management: “We fully expect to recover this margin impact over time.”
• Read-Through for IR: This is the most important margin read-through for IR. ITW’s price-cost lag narrative is nearly identical to IR’s — tariff pricing is dilutive in H1 but expected to turn more positive in H2. ITW’s confirmation that the lag is real but temporary (and improving in Q4) validates IR’s H2 margin recovery guide.
• Order Activity Ahead of Revenue in Welding & Test/Measurement: ITW noted “order activity in welding and test measurement electronics has been a good bit ahead of the revenue rates,” creating “a good bit more backlog there than normal.”
• Read-Through for IR: Positive for IR’s ITS tool and compressor businesses — backlog building ahead of revenue conversion is consistent with IR’s book-to-bill above one and supports H2 revenue acceleration.
• 2027 Incremental Margins of 40–45%: ITW guided for 2027 incremental margins of “40 to 45%” driven by enterprise initiatives and new products at higher margins.
• Read-Through for IR: Positive for IR’s longer-term margin expansion story (ITS targeting 30% by 2027, PST mid-30s) — if ITW can deliver 40%+ incrementals in 2027, IR’s targets look achievable.

Xylem Inc. (XYL) — Q2 2026 Earnings Call, July 28, 2026

Relevance to IR: XYL is a peer in flow control, water infrastructure, and life sciences-adjacent markets. Its commentary on water/utility demand, life sciences, China, and M&A is a read-through for IR’s PST segment and broader industrial end markets.

• Water Infrastructure Demand Healthy (H2 2026 Outlook): XYL reported water orders up double digits in both Q1 and Q2, with the funnel “up about 30% versus last year.” Management expects “water to be up about low single digits for the year with a strong second half.” Municipal demand “remains healthy, supported by strong infrastructure spending and backlog execution.”
• Read-Through for IR: Positive for IR’s ITS blower and vacuum businesses that serve water/wastewater treatment end markets. Healthy municipal infrastructure spending supports IR’s long-cycle project funnel.
• Life Sciences & Food/Beverage Demand Growing: XYL highlighted “similar opportunities emerging across high growth industrial sectors such as food and beverage and life sciences, where water is increasingly central to quality and operational performance.” The company expects “accretive growth coming from high growth verticals” including life sciences.
• Read-Through for IR: Directly supportive of IR’s PST life sciences growth narrative. Multiple peers (DOV, XYL) are seeing accelerating life sciences demand, validating IR’s double-digit life sciences order growth in Q1 and the expectation for continued momentum in Q2.
• China Stabilizing but Challenging: XYL described China as “a challenging market” but noted it “has stabilized a bit” with “a couple data center wins within the country.” China expected to be ~2% of XYL revenue in 2026. H2 expected to be “sequentially similar from a total volume perspective to the first half” with easier year-over-year comps.
• Read-Through for IR: Consistent with IR’s China narrative — the market has reset (IR: from ~15% to ~11% of revenue) and is now delivering positive organic order growth through self-help and share gains. XYL’s “stabilized” characterization supports IR’s view that China is no longer a meaningful headwind.
• Electric Metering Delays — Revenue Guidance Narrowed: XYL narrowed its full-year organic revenue guidance to 2–3% (from 2–4%) due to “mix electric project delays.” However, EPS guidance was raised due to share repurchases and higher margins. Management: “Affordability concerns and a more cautious capital spending environment ahead of upcoming elections have slowed down near-term investment.”
• Read-Through for IR: Mild caution flag — long-cycle project delays are not unique to IR (Middle East) but are a broader theme. However, XYL’s ability to raise EPS despite a revenue miss suggests margin execution can offset volume shortfalls, which is consistent with IR’s own EPS-beats-despite-margin-pressure track record.
• AI / Data Center as a Growing Water Demand Driver: XYL highlighted data center revenue expected to increase ~200% in 2026, with data centers projected to be ~2% of revenue by year-end. Management: “The growth of AI is making water a more strategic input across a broader ecosystem.”
• Read-Through for IR: Positive for IR’s ITS compressed air and vacuum businesses that serve data center cooling and semiconductor manufacturing end markets. The AI infrastructure build-out is a multi-year tailwind for industrial flow control.
• M&A Valuations Starting to Soften: XYL noted M&A valuations are “probably starting to soften a little bit” with “some signals” but “not aligned to where the market is.” XYL tracking toward $1B of M&A capital deployment per year.
• Read-Through for IR: Consistent with DOV’s commentary on improving M&A availability. Softening valuations could benefit IR’s bolt-on M&A strategy, potentially improving deal economics on the 10+ LOIs currently in the pipeline.